Marpai Yönetim

Yönetim kriter kontrolleri 0/4

Marpai CEO'su Damien Lamendola, Nov2023 tarihinde atandı, in görev süresi 3.58 yıldır. şirketin hisselerinin 37.22% doğrudan sahiptir ve bu hisselerin değeri $ 7.27M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 2.7 yıldır.

Anahtar bilgiler

Damien Lamendola

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	37.2%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	2.7yrs

Son yönetim güncellemeleri

Recent updates

Revenues Not Telling The Story For Marpai, Inc. (NASDAQ:MRAI) After Shares Rise 30%

Apr 07

Investors Still Aren't Entirely Convinced By Marpai, Inc.'s (NASDAQ:MRAI) Revenues Despite 34% Price Jump

Feb 16

Market Might Still Lack Some Conviction On Marpai, Inc. (NASDAQ:MRAI) Even After 106% Share Price Boost

Dec 19

Not Many Are Piling Into Marpai, Inc. (NASDAQ:MRAI) Stock Yet As It Plummets 28%

Jun 29

Marpai rallies after directors buy shares

Aug 19

Marpai to acquire Maestro Health for $22.1M

Aug 04

CEO

Damien Lamendola (67 yo)

less than a year

Görev süresi

Mr. Damien Francis Lamendola is Director at Marpai, Inc. and Marpai Health, Inc. since April 1, 2021. He serves as Chief Executive Officer at Marpai, Inc since November 06, 2023. He served as Chief Executi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Damien Lamendola	CEO & Director	less than a year	Veri yok	37.22% $ 7.3m
Steve Johnson	CFO & Company Secretary	less than a year	Veri yok	2.68% $ 522.6k
John Powers	President & COO	less than a year	Veri yok	0% $ 0
Eli David	Co-Founder & Chief Science Advisor	no data	Veri yok	Veri yok
Pamela Burns	Vice President of Enterprise Sales	3.3yrs	Veri yok	Veri yok
Richard Brewer	Chief Strategy Officer	less than a year	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: MRAI 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Damien Lamendola	CEO & Director	3.6yrs	Veri yok	37.22% $ 7.3m
Winston Churchill	Member of Advisory Board	no data	Veri yok	Veri yok
Yaron Eitan	Chairman of the Board	3.6yrs	Veri yok	4.9% $ 956.3k
Robert Pons	Independent Director	less than a year	Veri yok	0.61% $ 119.6k
Sagiv Shiv	Independent Director	1.8yrs	Veri yok	0.44% $ 85.2k
Mohsen Moazami	Independent Director	2.7yrs	Veri yok	0.25% $ 49.7k
Jennifer Calabrese	Independent Director	less than a year	Veri yok	0% $ 0
Ariel Zamir	Member of Advisory Board	no data	Veri yok	Veri yok
Colleen DiClaudio	Independent Director	3.1yrs	Veri yok	0.44% $ 85.2k
Michael Paas	Member of Advisory Board	no data	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MRAI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Marpai Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently sold US$105k worth of stock

Marpai, Inc. Announces Executive Appointments

Marpai, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently bought US$1.5m worth of stock

Co-Founder & Chairman of the Board recently bought US$193k worth of stock

Marpai, Inc. Appoints John Powers as President

Recent updates

Marpai, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Marpai, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Marpai, Inc.(OTCPK:MRAI) dropped from S&P TMI Index

Marpai, Inc.(OTCPK:MRAI) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Independent Director recently sold US$105k worth of stock

Full year 2023 earnings released: US$4.14 loss per share (vs US$5.23 loss in FY 2022)

Consensus revenue estimates decrease by 12%, EPS upgraded

Marpai, Inc. to Report Q1, 2024 Results on May 09, 2024

Marpai, Inc. Announces Executive Appointments

Marpai, Inc. announced that it has received $11.83 million in funding from JGB Management Inc.

Revenues Not Telling The Story For Marpai, Inc. (NASDAQ:MRAI) After Shares Rise 30%

Full year 2023 earnings: EPS misses analyst expectations

Marpai, Inc., Annual General Meeting, May 06, 2024

Nasdaq Panel Grants Marpai's Request for Extension to Comply with Continued Listing Requirements

CEO & Director recently bought US$1.5m worth of stock

Marpai, Inc. announced that it expects to receive $1.5015 million in funding

Marpai, Inc. Provides Impairment Guidance for the Fourth Quarter of 2023

Investors Still Aren't Entirely Convinced By Marpai, Inc.'s (NASDAQ:MRAI) Revenues Despite 34% Price Jump

Marpai, Inc. announced that it has received $1.7 million in funding from Libertas Funding, LLC

Co-Founder & Chairman of the Board recently bought US$193k worth of stock

Marpai, Inc. announced that it expects to receive $1.216464 million in funding

Marpai, Inc. Appoints John Powers as President

New major risk - Shareholder dilution

Market Might Still Lack Some Conviction On Marpai, Inc. (NASDAQ:MRAI) Even After 106% Share Price Boost

Co-Founder & Chairman of the Board recently bought US$99k worth of stock

Marpai, Inc. announced that it expects to receive $0.2955 million in funding

Marpai, Inc. Announces Board Changes

Marpai Receives Delisting Notice from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement and its Securities to be Delisted from the Nasdaq Capital Market

CEO & Director recently bought US$239k worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

New major risk - Share price stability

Marpai, Inc. has withdrawn its Follow-on Equity Offering.

Marpai Inc. Announces CEO Changes

Marpai Receives Non-Compliance Notice From Nasdaq

Marpai, Inc. Executes A Separation Agreement with Mr. Lutz Finger, President of Product and Development

New major risk - Market cap size

New major risk - Revenue and earnings growth

Marpai, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Marpai, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Consensus EPS estimates upgraded to US$2.40 loss

Marpai, Inc. Provides Revenue Guidance for Second Quarter 2023

Marpai Announces Reverse Stock Split in an Effort to Regain Compliance with Nasdaq's Listing Rules

Not Many Are Piling Into Marpai, Inc. (NASDAQ:MRAI) Stock Yet As It Plummets 28%

Marpai, Inc. Launches Marpai Connect Platform to Predict and Help Modify Risk in Healthcare

Marpai, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2023

Marpai, Inc. Hires Gonen Antebi as Chief Operating Officer

Marpai, Inc. Announces Management Changes

Marpai Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Marpai Introduces Chronic Condition Management to Improve Outcomes for Employer Health Plan Members

High number of new and inexperienced directors

Marpai, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Director recently bought US$100k worth of stock

Marpai Launches MarpaiRx Pharmacy Benefit Management Solution to Decrease Prescription Costs

Co-Founder & Chairman of the Board recently bought US$138k worth of stock

Marpai rallies after directors buy shares

Marpai, Inc. (NasdaqCM:MRAI) signed an agreement to acquire Maestro Health for $22.1 million.

Marpai to acquire Maestro Health for $22.1M

Marpai, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Co-Founder & Chairman of the Board recently bought US$105k worth of stock

Marpai, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Marpai, Inc. to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Marpai, Inc., Annual General Meeting, May 31, 2022

Marpai, Inc. Provides Revenue Guidance for the First Quarter of 2022

High number of new and inexperienced directors

CEO